qz
39h ago
16°
Gap slashed its full-year sales forecast after Old Navy badly missed
Old Navy comparable sales fell 4% in the second quarter, worse than expected, dragging down Gap's annual revenue target
qz
32h ago
15°
Trump is moving to let ranchers process their own meat, calling Big Four a monopoly
Four companies control about 85% of U.S. meat processing; Agriculture Secretary Brooke Rollins promised "big announcements" starting Monday
qz
34h ago
15°
Will Revenue Improvement Strengthen FirstEnergy's Long-Term Outlook?
FE's rising revenues, data-center demand and $36B Energize365 plan support rate-base expansion and long-term earnings growth.
qz
34h ago
15°
Can Long-Term Agreements Strengthen Hexcel's Growth Prospects?
HXL's long-term aerospace agreements with Boeing and Deutsche Aircraft aim to boost revenue visibility and support demand for advanced composites.
qz
31h ago
15°
Accessible tech helps small businesses overcome costs, labor gaps, and entry barriers
Accessible technology helps small businesses lower startup costs, simplify training, address labor gaps, and expand into new technical services.
qz
34h ago
14°
RHI Shares Rise 87.6% in Six Months: Here's What You Should Know
Robert Half's 87.6% six-month stock gain reflects its above-industry ROE, improving cash flow and steady shareholder returns.
qz
34h ago
14°
Are Investors Undervaluing 8x8 (EGHT) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we a
qz
34h ago
14°
Is Acme United (ACU) Outperforming Other Consumer Discretionary Stocks This Year?
Here is how Acme United Corporation. (ACU) and ASICS Corporation Unsponsored ADR (ASCCY) have performed compared to their sector so far this year.
qz
34h ago
14°
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Illumina (ILMN) have performed compared to their sector so far this year.
qz
37h ago
14°
FDA approved Gilead's new once-daily HIV pill for patients on complex regimens
Bixlenvo combines two existing Gilead drugs into a single tablet for adults whose virus is suppressed but who can't use current one-pill options